Paper2402017
Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.
Kelner MJ and 2 others. J Natl Cancer Inst, 1990. Cited by 74 papers, by iCite.
Cite this record
ConductScience Library. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. Papers, record 2402017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2402017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Drug Screening Assays, Antitumor | Major topic |
| Animals | |
| Biological Transport | |
| Cell Line | |
| Cell Survival | |
| Humans | |
| Kinetics | |
| Polycyclic Sesquiterpenes | |
| Sesquiterpenes |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-23100 | NCI NIH HHS | United States | P30CA023100 | PubMed and NIH | NIH RePORTER |
| CA-45568 | NCI NIH HHS | United States | R01CA045568 | PubMed and NIH | NIH RePORTER |
| RR-08135 | NCRR NIH HHS | United States | S06RR008135 | PubMed and NIH | NIH RePORTER |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42634105 | Mycotoxins in Basidiomycete Mycelium and Fruiting Bodies: Implications for Eu Novel Food Assessment and Selected International Regulatory Frameworks. | Compr Rev Food Sci Food Saf | 2026 | https://conductscience.org/library/papers/42634105 | PubMed |
| 39858827 | Spore-Derived Isolates from a Single Basidiocarp of Bioluminescent Omphalotus olivascens Reveal Multifaceted Phenotypic and Physiological Variations. | Microorganisms | 2025 | https://conductscience.org/library/papers/39858827 | PubMed |
| 36012321 | Antitumor Effects of a New Retinoate of the Fungal Cytotoxin Illudin M in Brain Tumor Models. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36012321 | PubMed |
| 35843931 | Optimization of the production process for the anticancer lead compound illudin M: process development in stirred tank bioreactors. | Microb Cell Fact | 2022 | https://conductscience.org/library/papers/35843931 | PubMed |
| 35643529 | Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks. | Microb Cell Fact | 2022 | https://conductscience.org/library/papers/35643529 | PubMed |
| 22895897 | Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. | J Pharmacol Exp Ther | 2012 | https://conductscience.org/library/papers/22895897 | PubMed |
| 21939268 | Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates. | Chem Res Toxicol | 2011 | https://conductscience.org/library/papers/21939268 | PubMed |
| 21443269 | Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes. | Chem Res Toxicol | 2011 | https://conductscience.org/library/papers/21443269 | PubMed |
| 20160945 | Observations in the Synthesis of the Core of the Antitumor Illudins via an Enyne Ring Closing Metathesis Cascade. | Tetrahedron Lett | 2009 | https://conductscience.org/library/papers/20160945 | PubMed |
| 19938810 | Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven. | J Org Chem | 2009 | https://conductscience.org/library/papers/19938810 | PubMed |
| 19668867 | Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues. | Mol Biosyst | 2009 | https://conductscience.org/library/papers/19668867 | PubMed |
| 17628744 | A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. | Invest New Drugs | 2007 | https://conductscience.org/library/papers/17628744 | PubMed |
| 16683074 | A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. | Invest New Drugs | 2006 | https://conductscience.org/library/papers/16683074 | PubMed |
| 12201500 | A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12201500 | PubMed |
| 11561687 | Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven. | Invest New Drugs | 2001 | https://conductscience.org/library/papers/11561687 | PubMed |
| 11291837 | A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. | Invest New Drugs | 2001 | https://conductscience.org/library/papers/11291837 | PubMed |
| 11291829 | Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. | Invest New Drugs | 2001 | https://conductscience.org/library/papers/11291829 | PubMed |
| 8913837 | Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. | Invest New Drugs | 1996 | https://conductscience.org/library/papers/8913837 | PubMed |
| 8575564 | Acylfulvenes, a new class of potent antitumor agents. | Experientia | 1996 | https://conductscience.org/library/papers/8575564 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2402017
GET https://conductscience.org/api/papers/v1/2402017/authors